Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bioavailability Study Clear all

Conditions: Healthy Volunteer
Interventions: GDC-0980, rabeprazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cancer
Interventions: Ipatasertib (capsule), Ipatasertib (tablet); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers
Interventions: Irafamdastat; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: vinorelbine tartrate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Infections, Bacterial
Interventions: 500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteer
Interventions: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Major Depressive Disorder
Interventions: CYB003, Psychotherapy, Placebo, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey

Conditions: Healthy Volunteers
Interventions: risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Subjects
Interventions: (Treatment A), (Treatment B); Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Acne Vulgaris
Interventions: Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 9 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension
Interventions: baxdrostat (formerly CIN-107) oral solution; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis
Interventions: GW856553; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy
Interventions: Dr Pepper sweetened with sucrose or high fructose corn syrup; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Healthy
Interventions: Clarithromycin 500mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: ALO-02 (Oxycodone Naltrexone); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: PF 06260414 solid dose formulation, PF-06260414 nanosuspension; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteoporosis
Interventions: Ronacaleret; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Healthy
Interventions: Lesinurad 400 mg, [14C]lesinurad (100 μg per 10 mL); Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: TAK-648 Tablet, TAK-648 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants

Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

Baxdrostat Bioavailability and Bioequivalence Study

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

Pharmacokinetics and Pharmacodynamics of Fructose

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants